Roche and Zealand Pharma reported that petrelintide, a peptide amylin-receptor agonist, met the primary endpoints in a Phase 2 obesity study with tolerability comparable to placebo. The trial achieved statistical weight-loss goals but produced mean reductions below some analyst forecasts, prompting questions about the drug’s competitive positioning against higher-efficacy GLP-1 and dual-agonist therapies. Roche and Zealand face a crowded anti-obesity market; the readout clarifies petrelintide’s safety profile but raises commercial differentiation issues. Sponsors will need larger, longer trials and clear positioning—possibly combination strategies or niche indications—to win payer and prescriber adoption against incumbents.